Clinical Trial

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated February 14, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-26; most recent amendment 2025-02-12.
Status change: Not Yet Recruiting → Recruiting 2024-09-04
Trial Details
NCT Number NCT06477536
Lead Sponsor Shanghai Huaota Biopharmaceutical Co., Ltd.
Conditions Generalized Pustular Psoriasis
Enrollment 33 participants
Start Date 2024-09-02
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-14